The European & Developing Countries Clinical Trials Partnership (EDCTP)

The aim of Global Health EDCTP3 JU is to reduce the individual, social and economic burden of poverty-related infectious diseases in sub-Saharan Africa, by supporting collaborative research to develop accessible, suitable and affordable medical interventions. Therefore, GH EDCTP3 JU targets the major infectious disease threats facing sub-Saharan Africa, including HIV, TB, malaria, lower respiratory tract infections, diarrhoeal diseases, neglected, emerging and re-emerging infections, as well as antimicrobial resistance and the impact of the climate crisis on infectious diseases.

The Global Health EDCTP3 programme focuses on all stages of clinical evaluation but particularly later-stage (phase III and phase IV) studies and has a particular focus on vulnerable population groups, including children, adolescents, pregnant and lactating women, older persons, and people with co-morbidities (including non-communicable diseases).

Multinational Funding and Calls

The EDCTP programme was founded in 2003 and is currently in the third funding period. The current EDCTP programme, Global Health EDCTP3, started in late 2022 and will run until 2031 with a total contribution of €1,8 billion of which up to €125 million are contributed by Germany.Several calls for proposals are announced each year, supported through three distinct types of Horizon Europe instruments.